Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Leblanc, Soline
26  Ergebnisse:
Personensuche X
?
1

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
Multiple Sclerosis and Related Disorders.  66 (2022)  - p. 104066 , 2022
Link: https://doi.org/10.1016/..
 
?
2

OA16.05 Socioeconomic Determinants of Late Diagnosis of Lun..:

Souquet, Pierre Jean ; Durand-Zaleski, Isabelle ; Chouaid, Christos...
Journal of Thoracic Oncology.  12 (2017)  1 - p. S306 , 2017
Link: https://doi.org/10.1016/..
 
?
3

Survival inequalities in patients with lung cancer in Franc..:

Chouaïd, Christos ; Debieuvre, Didier ; Durand-Zaleski, Isabelle...
PLOS ONE.  12 (2017)  8 - p. e0182798 , 2017
Link: https://doi.org/10.1371/..
 
?
4

Burden of Clostridium difficile Infections in French Hospit..:

Leblanc, Soline ; Blein, Cécile ; Andremont, Antoine..
Infection Control & Hospital Epidemiology.  38 (2017)  8 - p. 906-911 , 2017
Link: https://doi.org/10.1017/..
 
?
5

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.msard.2022.104066.  , 2022
Link: https://ehesp.hal.scienc..
 
?
6

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.msard.2022.104066.  , 2022
Link: https://ehesp.hal.scienc..
 
?
7

Trends in disease-modifying therapy use in patients with mu..:

Leblanc, Soline ; Lefort, Mathilde ; Le Page, Emmanuelle..
info:eu-repo/semantics/altIdentifier/doi/10.1080/14737175.2022.2061950.  , 2022
Link: https://hal.ehesp.fr/hal..
 
?
8

Trends in disease-modifying therapy use in patients with mu..:

Leblanc, Soline ; Lefort, Mathilde ; Le Page, Emmanuelle..
info:eu-repo/semantics/altIdentifier/doi/10.1080/14737175.2022.2061950.  , 2022
Link: https://hal.ehesp.fr/hal..
 
?
9

Trends in disease-modifying therapy use in patients with mu..:

Leblanc, Soline ; Lefort, Mathilde ; Le Page, Emmanuelle..
info:eu-repo/semantics/altIdentifier/doi/10.1080/14737175.2022.2061950.  , 2022
Link: https://hal.ehesp.fr/hal..
 
?
10

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.msard.2022.104066.  , 2022
Link: https://ehesp.hal.scienc..
 
?
11

Trends in disease-modifying therapy use in patients with mu..:

Leblanc, Soline ; Lefort, Mathilde ; Le Page, Emmanuelle..
info:eu-repo/semantics/altIdentifier/doi/10.1080/14737175.2022.2061950.  , 2022
Link: https://hal.ehesp.fr/hal..
 
?
12

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.msard.2022.104066.  , 2022
Link: https://ehesp.hal.scienc..
 
?
13

Trends in disease-modifying therapy use in patients with mu..:

Leblanc, Soline ; Lefort, Mathilde ; Le Page, Emmanuelle..
info:eu-repo/semantics/altIdentifier/doi/10.1080/14737175.2022.2061950.  , 2022
Link: https://hal.ehesp.fr/hal..
 
?
14

Disease reactivation after fingolimod cessation in Multiple..:

Callens, Alix ; Leblanc, Soline ; Le Page, Emmanuelle...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.msard.2022.104066.  , 2022
Link: https://ehesp.hal.scienc..
 
?
15

Disease-modifying therapy usage in patients with multiple s..:

Leblanc, Soline ; Roux, Jonathan ; Tillaut, Hélène..
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neurol.2021.04.006.  , 2021
Link: https://ehesp.hal.scienc..
 
1-15